Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate compliance, tolerability, safety, efficacy and caregiver burden of
rivastigmine patch 10 cm² treatment in people with Alzheimer's disease (MMSE 10-26)
initiating therapy for the first time with a cholinesterase inhibitor, and in patients who
were unresponsive to previous cholinesterase inhibitor treatment in a community setting.